Dr. Sumithira Vasu, MD
Claim this profileOhio State University Comprehensive Cancer Center
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Myeloid Leukemia
9 reported clinical trials
12 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
CD22 positive
CD19 positive
CD20 positive
2Acute Myeloid Leukemia
HLA-A positive
HLA-A negative
HLA positive
Affiliated Hospitals
Clinical Trials Sumithira Vasu, MD is currently running
Inotuzumab Ozogamicin Post-Transplant
for Leukemia and Lymphoma
This study has two phases, Phase I and Phase II. The main goal of the Phase I portion of this research study is to see what doses post-transplant inotuzumab ozogamicin can safely be given to subjects without having too many side effects. The Phase II portion of this study is to see what side effects are seen with medication after transplant. Inotuzumab ozogamicin is a combination of an antibody and chemotherapy which has been shown to have significant activity against relapsed/refractory acute lymphocytic leukemia (ALL). Inotuzumab ozogamicin is considered experimental in this study.
Recruiting1 award Phase 1 & 2
CAR T-cell Therapy
for Lymphoma and Leukemia
This trial tests the safety and best dose of a new treatment using modified immune cells (CAR T-cells) for patients with certain recurring or hard-to-treat lymphoid cancers. The treatment involves giving patients a brief period of chemotherapy followed by an infusion of these specially designed cells to target and kill cancer cells. Anti-CD19 CAR T-cells currently represent transformational therapy for relapsed/refractory aggressive B-cell lymphomas where durable remissions can be induced in patients with previously incurable chemotherapy-refractory disease.
Recruiting1 award Phase 1
More about Sumithira Vasu, MD
Clinical Trial Related7 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Sumithira Vasu, MD has experience with
- Anti-CD19/CD20/CD22 CAR T-Cells
- Cyclophosphamide
- Fludarabine Phosphate
- NEXI-001 T Cell Product
- Unlicensed Cryopreserved Cord Blood Units
- Vitamin A
Breakdown of trials Sumithira Vasu, MD has run
T-Lymphoblastic Leukemia/Lymphoma
Acute Myeloid Leukemia
Myeloid Leukemia
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sumithira Vasu, MD specialize in?
Sumithira Vasu, MD focuses on T-Lymphoblastic Leukemia/Lymphoma and Acute Myeloid Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved CD22 positive patients, or patients who are CD19 positive.
Is Sumithira Vasu, MD currently recruiting for clinical trials?
Yes, Sumithira Vasu, MD is currently recruiting for 3 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Sumithira Vasu, MD has studied deeply?
Yes, Sumithira Vasu, MD has studied treatments such as Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate.
What is the best way to schedule an appointment with Sumithira Vasu, MD?
Apply for one of the trials that Sumithira Vasu, MD is conducting.
What is the office address of Sumithira Vasu, MD?
The office of Sumithira Vasu, MD is located at: Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States. This is the address for their practice at the Ohio State University Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.